Neuro Oncol. 2026 Nov 14. pii: noag286. [Epub ahead of print]
Philipp Lohmann,
Carla Pitarch-Abaigar,
Mariam Aboian,
Hamed Akbari,
Wenya Linda Bi,
Thomas C Booth,
Evan Calabrese,
Keith George Ciantar,
Christos Davatzikos,
Benjamin M Ellingson,
Bradley Erickson,
Shahriar Faghani,
Anahita Fathi Kazerooni,
Norbert Galldiks,
Julia Hilgers,
Jana Ivanidze,
Rajan Jain,
Benjamin H Kann,
Philipp Karschnia,
Konstantinos Koukoutegos,
Dominic LaBella,
Marius George Linguraru,
Janine M Lupo,
Ali Nabavizadeh,
Martha Nowosielski,
Yae Won Park,
Jason Parker,
Ghulam Rasool,
John Y Rhee,
Chong Hyun Suh,
Pallavi Tiwari,
Javier E Villanueva-Meyer,
Philipp Vollmuth,
Jan-Michael Werner,
Benedikt Wiestler,
Raymond Y Huang,
Spyridon Bakas.
Artificial intelligence (AI) has become central to neuro-oncological imaging, impacting clinical and scientific workflows. In clinical practice, AI-based image reconstruction and noise reduction expedite the generation of advanced multiparametric MRI and PET scans. Automated segmentation and volumetric analysis improve reproducibility, speed, and standardization of tumor quantification and response assessment. In research, large language and multimodal models extract structured information from radiology reports and medical records. Collaborative initiatives, such as BraTS and FeTS, have established standardized, privacy-compliant frameworks for large-scale quantitative analyses. Tumor-specific applications include noninvasive molecular profiling in gliomas, grading and recurrence prediction in meningiomas, detection and response assessment in brain metastases, and pediatric-specific modeling aligned with RAPNO. However, AI models remain sensitive to technical and biological variations across institutions, limiting their clinical utility unless appropriate training and validation is performed. Nevertheless, progress is evident in prospective, biopsy-validated infiltration mapping, assessment of resection extent aligned with RANO-Resect, and standardization through AI-RANO. Emerging directions include foundation models, uncertainty estimation, federated learning, AI-enhanced ultra-low-field MRI, and dual-tracer PET. When used as a decision-support tool rather than a replacement for the imaging team, AI can increasingly improve the utility, reproducibility, and efficiency of quantitative, multiparametric imaging in patients with brain tumors.
Keywords: AI-RANO; PET/MRI; clinical translation; federated learning; foundation models